The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition. [electronic resource]
Producer: 20180423Description: 46915-46927 p. digitalISSN:- 1949-2553
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cell Movement -- genetics
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Cerebellar Neoplasms -- drug therapy
- Dose-Response Relationship, Drug
- Drug Synergism
- Etoposide -- pharmacology
- Humans
- Indazoles -- pharmacology
- Medulloblastoma -- drug therapy
- Molecular Targeted Therapy
- Phosphoinositide-3 Kinase Inhibitors
- Piperidines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinazolines -- pharmacology
- Signal Transduction -- drug effects
- Sulfonamides -- pharmacology
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.